In summary, 15 polymorphisms were found to be associated with variations in chemotherapy clinical outcome or toxicity in cancers such as breast, gastrointestinal and renal, all of them located in non-translated regions of the NR1I2 gene. This evidence concerns the gene NR1I2 and cancer.